Xiaoxia Shi
Nanyang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Correction: Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.
Journal: Diabetologia
Published: March 19, 2026
Clinical application of ozone hydrotherapy combined with scalp complex acid treatment for moderate to severe scalp seborrheic dermatitis.
Journal: Frontiers in medicine
Published: January 21, 2026
Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2).
Journal: Nature communications
Published: November 20, 2025
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.
Journal: Diabetologia
Published: May 01, 2025
Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: Nature communications
Published: March 31, 2025
Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study.
Journal: Journal of the American College of Cardiology
Published: February 12, 2025
Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial.
Journal: Atherosclerosis
Published: February 10, 2025
Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials.
Journal: Cardiovascular diabetology
Published: January 21, 2025
Showing 1-8 of 8
Last Updated: 09/26/2026